



## KLHL5 knockdown increases cellular sensitivity to anticancer drugs

### SUPPLEMENTARY MATERIALS




**Supplementary Figure 1: Pearson correlations between KLHLs and anticancer compounds.** Histogram for KLHLs indicates that KLHL5 possesses a high number of moderate or high negative correlations with compounds ( $< -0.4$ ) and a distribution of correlations with the ~20,000 compounds that is shifted in distribution towards a negative correlation.




**Supplementary Figure 2: Highly synergistic/antagonistic drugs with KLHL5 knockdown.** Drugs with highest synergy or antagonism with KLHL5 knockdown. Cell line (CL) SN12C (S) was treated at 0.1 and 0.01  $\mu$ M concentrations and OVCAR-8 (O) was treated at 1 and 0.1  $\mu$ M concentrations. The viabilities upon treatment with compounds with the highest differences between the expected (knockdown only x drug only) and observed (knockdown and drug combined treatment) from the screening tests are shown.

### Network: Associated with KLHL5



ontology and false discovery rate:  
 GO: 0007049 cell cycle 3.75E-30  
 GO: 0016567 protein ubiquitination 4.12E-42  
 GO: 1903047 mitotic cell cycle process 3.78E-34

### Network: All KLHLs



**Supplementary Figure 3: STRING network analysis.** String-db.org was consulted for information about interactions between KLHLs as well as proteins known or suspected to associate with KLHL5.